Otelixizumab
- Generic Name
- Otelixizumab
- Drug Type
- Biotech
- CAS Number
- 881191-44-2
- Unique Ingredient Identifier
- I5HF2X04PB
Overview
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.
Background
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.
Indication
Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.